Have we finished having a meltdown yet? Let's face it, we're crap. Season after season of stupidity, but still I fear Fosun selling up to someone worse. #wwfc
As a happy clapper, I made my mind up halfway through the Brighton game. Utter crap and a ridiculous appointment.#wwfc
Ill be happy when the silly season is over, im already much happier with the squad. Nb 1 priority was a CB. #wwfc
Im a forgiving, positive fan, not watching today, but Brighton had warning signs. It seems today is not much better. It's going to be a long season! #wwfc
Bored of this week, nothing is going to squash my enthusiasm for the first home game of the season. We might have our team (pack) back!#wwfc
It's been a soap opera of laughable proportions, but didn't everyone write off Eddie Howe joining Newcastle? Just sayin.#wwfc
Bored of all this, two egos going at each other, current evidence is that the players moral is good. So I hope Lop stays. #wwfc
Watch us smash Luton resulting in Fosun thinking no further signings are needed! #wwfc
Is anyone covering @PortageBiotech and their poster on IMPORT-201 ?@OncoAlert #ASCO23
Looking forward to seeing the work Ian and team have done since the previous asco
Posters out, anyone fancy paying the $1399 and sticking it on here? No, oh well we'll wait.... $prtg
Replying to @JacobPlieth
$PRTG early stage in p1/p2 ,wont necessary see the press others receive,their abstract is worth a look
Strong early efficacy results at low/mid dose in their inkt agonist treating nsclc stage 4.
Patients had not repsonded to previous therapies and PD-1.
meetings.asco.org/abstracts-…
$PRTG It's only worth promoting stocks on Twitter when there's something to shout about, this is it. ASCO is weeks away, expect a rise to previous levels from here.
Replying to @jamvest20
To note stable disease(SD) in 10no lesion given this is stage 4 nsclc patients is equally as credible at their low dose (1-3mg) imm60 could be a tangible alternative to both chemo and or PEM . 12month progression free survival will be very telling $PRTG
Take a listen and realise the potential of $PRTG. At this price it's the bargain of the century. ASCO is weeks away where the data will prove the investment.
Check out this episode of @molecule2markt podcast, featuring our CEO Ian Walters! Ian discusses his background in the industry, along with Portage’s business model and progress in the clinic. Learn more about what makes Portage unique here: bit.ly/426vsA1
$PRTG a Board full of experience, always good when a presentation references billion dollar exits! @PortageBiotech has 'Multiple Phase 1b/2 Data Catalysts in 2023 and 2024', an easy sit and hold play









